Emergen Research Logo
Growing incidences of organ failure is one of the significant factors influencing the market growth.
Market Size – USD 18.49 Billion in 2019, Market Growth – CAGR of 7.3%, Market Trends”— Emergen…
Source: news.google.com – Read more
Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs
Merck’s Lipfendra is the first FDA-approved pill in the class of cholesterol-lowering drugs called PCSK9 inhibitors. While peptides are typically injected, Lipfendra is a macrocyclic
